Bayer | Pharmaceuticals

❗One week to go! 📅 On October 30, at 16:30 CET, join our LinkedIn Live event, Nothing Left Unsaid: Dialogues on Stroke that Matter, to hear from stroke survivors Kevin and Stacie. They will be joined by Dr. Mira Katan, as they share what they faced, what support they needed, and what they wish had been part of their care journey. 📌 Save your spot and be part of the conversation: http://spr.ly/6044Aa4pr Their experiences offer a powerful lens into the realities of recovery and the critical importance of secondary stroke prevention. Let’s listen, reflect, and work together! Secondary stroke deserves another look. #NoToTwo #TheInvisibleMadeVisible #StrokeActionNow #WorldStrokeDay This campaign has been developed and fully funded by Bayer.

What is next-generation sequencing? Next-generation sequencing (NGS) is a test that can look closely at a tumour's unique genomic alterations. For patients diagnosed with advanced non-small cell lung cancer (NSCLC), testing for HER2 mutations is recommended. NGS is a critical tool for accurately identifying these specific genomic changes, so that patients can receive more targeted therapies for their cancer type. #TeamBayer is passionate about advancing the field of genomic testing and personalized treatment in oncology, striving to provide the right treatment to the right patient at the right time. #ESMO25

Glenna, who lives with HER2-mutant non-small cell lung cancer, shares her personal journey to diagnosis.        Screening and early detection is one of the most effective ways to detect lung cancer at its earliest stages, when its most treatable.      We are committed to advancing research and the development of innovative therapies. Find out more about how we are advancing lung cancer through purposeful innovation. Link in comments.    #TeamBayer #ESMO25 #OncologyInspired #HealthforAll  

With World Stroke Day on the horizon, #TeamBayer continue to shine a light on the real experiences of survivors and care partners, and the urgency of preventing second strokes. Secondary stroke deserves another look. #NoToTwo #TheInvisibleMadeVisible #StrokeActionNow #WorldStrokeDay 1. Kolmos M, et al. J Stroke Cerebrovasc Dis. 2021;30(8):105935 This campaign has been developed and fully funded by Bayer.

Researchers understand how disruptive and unpredictable menopause symptoms can be in daily life. That’s why ongoing studies are focused on finding better ways to help women manage their wellbeing and feel supported during this important stage. Bayer will be contributing to the conversation at The Menopause Society , where experts will gather to share the latest research, practical guidance, and innovative approaches to support women’s health and shape the future of menopause care. #MenopauseSocietyMtg #HealthForAll #HungerForNone #TeamBayer

Join us for our LinkedIn Live event, ‘Overcoming Barriers to Diagnosis of Chronic Kidney Disease in Type 2 Diabetes’. Register now to hear our expert panel discuss the benefits of regular UACR testing in people living with type 2 diabetes, with a focus on improving outcomes and reducing cardiovascular (CV) risk. Hear about actions and opportunities to overcome barriers that limit the uptake of UACR testing. Stay tuned for updates as we reveal our panel in the coming weeks – and get your questions ready for our live Q&A! Drop them in the comments or ask them live during the session.

Cancer can impact anyone, anywhere. By 2050, global cancer cases are expected to rise by 75%. That’s why we’re pushing the boundaries of science to develop next-generation targeted therapies that have the potential to truly change the lives of people living with the disease. #ESMO25 #OncologyInspired http://spr.ly/6040AL9YI

We’re in Berlin this weekend for the #ESMO25 Congress and our team is excited to jump into the action! #TeamBayer is sharing new insights and innovations from across our oncology portfolio and connecting with researchers and colleagues to explore the latest breakthroughs in cancer science.

#NEWS: New positive results in HER2-mutant non-small cell lung cancer (#NSCLC) have been published in the New England Journal of Medicine and presented at ESMO 2025 today. Patients with HER2-mutant NSCLC face limited treatment options and poor prognosis, highlighting an urgent need for more effective therapies. This milestone reflects our ongoing commitment to advancing cancer care where it is needed most. Learn more: https://www.nejm.org/ #OncologyInspired

#ProstateCancer is the most common cancer in men — and new cases are projected to rise from 1.4 million in 2020 to 2.9 million by 2040.    Advances in non-invasive imaging, like prostate MRI, have the potential to re-shape the way we approach diagnosis, not only supporting accurate detection — they may also help men avoid unnecessary biopsies.   At a recent media event at our Bayer Pharmaceuticals headquarters in Berlin, we were proud to share insights into the latest innovations driving progress in this field. Together, we’re working toward a future where better tools mean better outcomes for patients. #ESMO25 #TeamBayer #BayerInRadiology